Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.71 +0.07 (+0.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Amphastar Pharmaceuticals: Q4 Earnings Insights
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021
Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / March 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Earnings Preview For Amphastar Pharmaceuticals
Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.... 
Via Benzinga
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 10th, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 3, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2021 ended December 31, 2021,... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
7 Safe Stocks to Rely On When the Market Swerves
When markets that have flown so high for so long start to tumble, along with an economy that transitioning, safe stocks are essential. 
Via InvestorPlace
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79. 
Via Investor's Business Daily
Top Russell 2000 Stocks: Trading Opportunities For Next Week
A security pattern traces the distinct movements of security prices that, once recognized, helps traders to make informed trading decisions. Let's look at some Russell 2000 stock opportunities by... 
Via Talk Markets
64 Biggest Movers From Yesterday
Gainers Calithera Biosciences, Inc. (NASDAQ: CALA) shares surged 55.7% to settle at $0.65 on Monday after Ladenburg Thalmann initiated coverage on the stock with a... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Calithera Biosciences (NASDAQ:CALA) shares moved upwards by 42.8% to $0.6 during Monday's regular session. As of 12:30 EST, Calithera Biosciences's stock... 
Via Benzinga
32 Stocks Moving In Monday's Mid-Day Session
Gainers FGI Industries Ltd. (NASDAQ: FGI) shares jumped 42.4% to $5.37 after surging 19% on Friday. The company, last week, priced its IPO at $6 per share. Knightscope, Inc. (... 
Via Benzinga
Maravai Lifesciences Stock Closes In Technical Benchmark, Hitting 80-Plus RS Rating
One key metric to look for in a stock is 80-plus RS Rating. Maravai Lifesciences stock just hit that mark, with a jump from 71 to 81 Monday. 
Via Investor's Business Daily
Amphastar Receives FDA Tentative Approval for Vasopressin
RANCHO CUCAMONGA, CA / ACCESSWIRE / December 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has tentatively approved the Company's... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Ligand Pharmaceuticals Sees RS Rating Rise To 92
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Amphastar Pharmaceuticals, inc (AMPH) Q3 2021 Earnings Call Transcript
AMPH earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Amphastar Pharmaceuticals: Q3 Earnings Insights
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021
Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / November 8, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8th, 2021
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 28, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2021 ended September 30,... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Amphastar Pharmaceuticals to Present at the Wells Fargo 2021 Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / September 2, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Amphastar Pharmaceuticals, inc (AMPH) Q2 2021 Earnings Call Transcript
AMPH earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021
Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / August 9, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9th, 2021
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2021 ended June 30, 2021,... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
18 Key Biopharma Catalysts To Keep An Eye On In Q3
Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Ne... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.